A phase III, randomized, observer-blind, active-controlled, parallel-group, multi-center study to evaluate immunogenicity and safety of a preventive COVID-19 vaccine EuCorVac-19 in healthy adults aged 18 years and older
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Enrollment
2,852
COVID-19 vaccine
COVID-19 vaccine
Trial site
Kinshasa, Democratic Republic of the Congo
The proportion of GMT of neutralizing antibody of EuCorVac-19 and ChAdOx1
Time frame: 14 days after the 2nd vaccination
The difference in neutralizing antibody SRR of EuCorVac-19 and ChAdOx1
Time frame: 14 days after the 2nd vaccination
Occurrence of solicited Adverse Events (AEs)
Time frame: Through 7 days after each vaccination
Occurrence of unsolicited Adverse Events (AEs)
Time frame: Through 28 days after the 2nd vaccination
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.